(Q51156844)

31 March 2018

title

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. (English)

1 reference

31 March 2018

0 references

1 reference

6

1 reference

31 March 2018

Staffan Nilsson

3

object named as

S Nilsson

1 reference

31 March 2018

Lars Rosengren

5

object named as

L Rosengren

1 reference

31 March 2018

Clas Malmeström

2

object named as

C Malmeström

1 reference

31 March 2018

author name string

M Axelsson

1

1 reference

31 March 2018

S Haghighi

4

1 reference

31 March 2018

publication date

1 January 2011

1 reference

31 March 2018

published in

Journal of Neurology

1 reference

31 March 2018

volume

258

1 reference

31 March 2018

issue

5

1 reference

31 March 2018

page(s)

882-888

1 reference

31 March 2018

https://scigraph.springernature.com/pub.10.1007/s00415-010-5863-2

exact match

0 references

cites work

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

An acidic protein isolated from fibrous astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

The glial scar and central nervous system repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Optimizing the association between disability and biological markers in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Neuronal intermediate filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Monoclonal antibodies selective for low molecular weight neurofilaments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Cerebrospinal fluid neurofilament and glial fibrillary acidic protein in patients with cerebral vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5863-2

Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability

21 January 2018

1 reference

12 December 2020

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

1 reference

12 December 2020

Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit

1 reference

12 December 2020

Cerebrospinal fluid markers in MS patients and their healthy siblings

1 reference

12 December 2020

1 reference

12 December 2020

Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease

1 reference

12 December 2020

Neurofilament light as a prognostic marker in multiple sclerosis

1 reference

12 December 2020

Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection

1 reference

12 December 2020

Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF.

1 reference

12 December 2020

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

1 reference

12 December 2020

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

12 December 2020

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

1 reference

12 December 2020

HLA-antigens and the prognosis of multiple sclerosis

1 reference

12 December 2020

10.1007/S00415-010-5863-2

Identifiers

DOI

1 reference

31 March 2018

1 reference

31 March 2018